United States Varicose Vein Treatment Devices Market By Type (Endo venous Ablation, Sclerotherapy, Surgical Ligation & Stripping), By End Use (Clinics, Hospitals, and Ambulatory Care Centers), By Region, Competition, Forecast & Opportunities, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 532.12 Million
CAGR (2026-2031)	5.84%
Fastest Growing Segment	Endo venous Ablation
Largest Market	South
Market Size (2031)	USD 748.01 Million

Market Overview

The United States Varicose Vein Treatment Devices Market will grow from USD 532.12 Million in 2025 to USD 748.01 Million by 2031 at a 5.84% CAGR. The United States Varicose Vein Treatment Devices Market encompasses a range of medical instruments, including endovenous ablation systems, sclerotherapy agents, and surgical tools designed to correct chronic venous insufficiency and treat enlarged, twisted veins. The primary drivers fueling this market include an aging population susceptible to venous elasticity loss and the rising prevalence of obesity, which places increased pressure on the lower extremities. Furthermore, the market is supported by a strong shift toward office-based, minimally invasive procedures that allow for faster patient recovery compared to traditional vein stripping. According to the Society for Vascular Surgery, in 2024, more than 1,000 healthcare sites actively contributed data to the Vascular Quality Initiative registries, reflecting the extensive clinical infrastructure now dedicated to monitoring vascular outcomes.

However, a significant challenge impeding broader market expansion is the restrictive nature of reimbursement policies. Many private insurers and government payers frequently classify varicose vein treatments as cosmetic unless specific, severe symptoms such as venous ulcers or intractable pain are documented. This stringent coverage criteria often forces patients to pay out-of-pocket, thereby limiting procedure volume and restricting overall market accessibility for non-emergent cases.

Key Market Drivers

The Rapid Expansion of the Geriatric Population and the Rising Prevalence of Chronic Venous Insufficiency serve as the primary engines for market growth. As the United States demographics shift toward an older median age, the incidence of venous valve degeneration increases significantly, necessitating therapeutic intervention for conditions ranging from cosmetic varicosities to severe venous stasis. This demographic pressure is compounded by lifestyle factors such as obesity and sedentary behavior, which exacerbate venous hypertension and drive the need for medical devices. According to the Society for Vascular Surgery, July 2025, chronic venous insufficiency affects up to 40% of Americans, creating a substantial and expanding patient pool requiring clinical management. This escalating disease burden directly correlates with the sustained demand for effective treatment devices.

Technological Advancements in Endovenous Ablation Devices are equally critical in propelling the market forward, particularly the shift from invasive surgeries to outpatient, minimally invasive modalities. Innovations such as non-thermal, non-tumescent (NTNT) systems and advanced radiofrequency ablation catheters have streamlined procedures, reduced recovery times, and improved safety profiles, thereby increasing patient throughput in specialized vein clinics. This trend is evident in recent industry performance; according to Boston Scientific, February 2025, in the 'Q4 2024 Financial & Operational Highlights', the Peripheral Interventions segment delivered a 21.0% increase in global net sales, underscoring the rapid adoption of these advanced technologies. Furthermore, indicating the broader sector's financial scale, according to Medtronic, June 2025, in the 'Annual Report for Fiscal Year Ending 4/25, 2025', the Cardiovascular Portfolio achieved net sales of $12.5 billion, reflecting the robust investment and revenue generation within the vascular care landscape.

Download Free Sample Report

Key Market Challenges

The restrictive nature of reimbursement policies significantly hampers the growth of the United States Varicose Vein Treatment Devices Market by limiting patient access and reducing the financial viability of procedures. Private insurers and government payers frequently categorize vein treatments as cosmetic, denying coverage unless the patient presents with advanced complications such as venous ulcers or debilitating pain. This stringent approval process discourages patients from seeking early intervention, as many cannot afford the substantial out-of-pocket costs associated with non-covered treatments. Consequently, the volume of elective but clinically beneficial procedures remains suppressed, directly reducing the demand for ablation systems and sclerotherapy agents.

Moreover, the market faces continued downward pressure on provider compensation, which disincentivizes the adoption of treatment technologies in office-based settings. Physicians encounter increasing administrative hurdles and declining payment rates that erode the profitability of performing venous interventions. According to the American Venous Forum, in 2024, the Centers for Medicare & Medicaid Services proposed a reimbursement reduction of approximately 2.8 percent for the physician fee schedule, signaling a tightening fiscal environment for vascular specialists. This trend of diminishing reimbursement forces many practices to limit their service offerings, thereby stifling the overall expansion of the market.

Key Market Trends

The Integration of Artificial Intelligence in Venous Mapping and Navigation is fundamentally reshaping diagnostic protocols by enhancing the precision of vascular imaging. Unlike traditional manual mapping, AI algorithms can now instantaneously analyze ultrasound data to identify reflux pathways and anatomical variations, significantly reducing procedural planning time. This technological leap addresses the need for standardized diagnostics in high-volume vein clinics, minimizing operator variability and improving treatment targeting. According to the National Institutes of Health, March 2025, in the study 'Does Artificial Intelligence Bring New Insights in Diagnosing Phlebological Diseases?', the implementation of AI-driven diagnostic workflows successfully decreased the time required for venous image analysis by more than 50 percent, illustrating the operational efficiency these tools offer to vascular specialists.

Concurrently, there is a marked Shift Toward Single-Use and Disposable Endovenous Catheter Systems, driven by the imperative to eliminate cross-contamination risks and optimize clinical workflows. As vein practices scale, the logistical burden of sterilizing reusable instruments has led providers to favor pre-packaged, sterile disposables that ensure consistent performance and patient safety. This transition is also supported by the financial predictability of single-use devices, which remove the hidden costs of reprocessing and enable faster room turnover between procedures. This demand is reflected in industrial performance; according to Becton, Dickinson and Company, November 2025, in the 'Fourth Quarter and Full Year Fiscal 2025 Financial Results', the Peripheral Intervention segment achieved mid-single-digit growth, underscoring the sustained market reliance on advanced disposable interventional tools.

Segmental Insights

Endovenous ablation represents the fastest-growing segment within the United States varicose vein treatment devices market due to a distinct shift toward minimally invasive procedures. Patients and practitioners increasingly prefer these techniques over traditional surgical vein stripping because they offer reduced recovery times and lower procedural risks. This expansion is further supported by the United States Food and Drug Administration, which has cleared numerous radiofrequency and laser ablation devices for safe outpatient use. Consequently, the ability to perform these treatments in office-based settings has significantly improved patient access and accelerated adoption across the country.

Regional Insights

The South United States maintains a leading position in the Varicose Vein Treatment Devices Market due to favorable demographic trends and established healthcare infrastructure. A significant concentration of the geriatric population, particularly in Florida, combined with higher obesity rates across the region drives the demand for venous interventions. Additionally, the broad availability of specialized vascular clinics and consistent reimbursement coverage from the Centers for Medicare & Medicaid Services facilitates patient access to necessary treatments. This combination of elevated patient volume and supportive regulatory frameworks ensures the continued market dominance of the Southern region.

Recent Developments

• In October 2024, Cook Medical released three-year data from the VIVO clinical study demonstrating the sustained safety and effectiveness of the Zilver Vena Venous Self-Expanding Stent. The results, published in the Journal of Vascular and Interventional Radiology, showed high patency rates across various patient subgroups, including those with post-thrombotic syndrome and non-thrombotic iliac vein lesions. This long-term research reinforced the device's utility in treating iliofemoral venous outflow obstruction, a key underlying factor in chronic venous disease. The study highlighted the stent's durability and its ability to maintain vessel openness in the challenging venous environment over an extended period.
• In July 2024, Theraclion announced the completion of patient treatments in its pivotal clinical trial required by the FDA for the Sonovein system. This milestone marked a critical step toward bringing the company's non-invasive, high-intensity focused ultrasound (HIFU) technology to the United States market for the treatment of varicose veins. The study, conducted at leading medical centers in the US and Europe, evaluated the safety and efficacy of the extracorporeal device, which treats superficial venous insufficiency without the need for catheters or incisions. The company stated that a twelve-month follow-up period would ensue before the final submission for marketing approval.
• In June 2024, Royal Philips launched the Duo Venous Stent System in the United States following its premarket approval from the FDA. The device was engineered to treat symptomatic venous outflow obstruction in patients suffering from chronic venous insufficiency, a condition often associated with severe varicose veins and leg swelling. The system features a unique design comprising two stents with distinct mechanical properties to address the specific challenges of venous anatomy, such as compression and flexibility. The company highlighted that this product launch significantly expanded its portfolio for treating deep venous disease and aimed to improve long-term patient outcomes in the vascular intervention market.
• In January 2024, VVT Medical announced a strategic distribution agreement with Methapharm to market the ScleroSafe platform throughout the United States. This collaboration aimed to leverage Methapharm's established commercial infrastructure to distribute the device, which had previously received FDA 510(k) clearance. The ScleroSafe system utilizes a proprietary dual-syringe technology to perform non-thermal, non-tumescent treatment for superficial varicose veins. The partnership was designed to facilitate broader patient access to this minimally invasive procedure, which integrates chemical ablation with mechanical management to treat varicosities efficiently without the need for tumescent anesthesia or large incisions.

Key Market Players

• AngioDynamics, Inc.
• Medtronic PLC
• Teleflex Incorporated
• Sciton, Inc.
• Dornier MedTech America, Inc.
• Merit Medical Systems
• Boston Scientific Corporation
• Candela Corporation
• Becton, Dickinson and Company

By Type	By End Use	By Region
Endo venous Ablation Sclerotherapy Surgical Ligation & Stripping	Clinics Hospitals Ambulatory Care Centers	Northeast Midwest South West

Report Scope:

In this report, the United States Varicose Vein Treatment Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• United States Varicose Vein Treatment Devices Market, By Type:

• Endo venous Ablation
• Sclerotherapy
• Surgical Ligation & Stripping

• United States Varicose Vein Treatment Devices Market, By End Use:

• Clinics
• Hospitals
• Ambulatory Care Centers

• United States Varicose Vein Treatment Devices Market, By Region:

• Northeast
• Midwest
• South
• West